VERA today
$28.91-$1.57 (-5.13%)close Nov 12, 2026Trend
DailyUptrend (confirmed)
4 hourBearish
1 hourStrong Bearish
15 minStrong Bearish
5 minExpanding
Daily trend turns down below $29.56
Key levels
Resistance$32.78
Resistance$29.56
Support$27.46
Support$24.84
Latest news & SEC filings
AnalystWedbush trims its valuation estimate for Vera Therapeutics to $29
AnalystWedbush keeps Neutral rating on Vera Therapeutics, cuts target to $29
All VERA news →About Vera Therapeutics
Vera Therapeutics develops medicines for people with immune system disorders. Its main drug candidate, atacicept, targets a kidney disease called immunoglobulin A nephropathy and related renal conditions. Another candidate, MAU868, is aimed at BK virus infections in organ transplant patients, while VT-109 is an earlier-stage program for diseases driven by B cells. The company holds global rights to these programs and is based in the United States.
Based on the company's 10-K filed Feb 26, 2026.
Nasdaq · Healthcare
Vera Therapeutics, Inc. (VERA)
What Is the Price Target for VERA?
SEPT Low Target
$29.00
SEPT Mid Target
$70.50
SEPT High Target
$91.00
Analyst Consensus
$70.50
Is VERA a Buy or Sell Right Now?
Thesis
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for VERA.
Start Free Trial →Is VERA Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$56.33
12
Moat Score
NONE
1/9
Piotroski Score
7.7
Altman Z-Score
What Is Smart Money Doing with VERA?
Insider Signal
SELLING
0 buys / 13 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Fordyce Marshall | director officer | Buy | 18,500 | $54K | Sep 2, 2026 |
| Fordyce Marshall | director officer | Sale | 18,500 | $650K | Sep 2, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →VERA Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
-69.45%
FCF Growth YoY
-78.2%
Revenue Trend
UNKNOWN
Dark Pool Trades for VERA
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for VERA, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:00:37 | $30.48 | 1,523 | $$46K | BUY |
| 21:00:37 | $30.48 | 2,393 | $$73K | BUY |
| 21:00:37 | $30.48 | 1,207 | $$37K | BUY |
| 21:00:34 | $30.48 | 2,300 | $$70K | BUY |
| 21:00:11 | $30.48 | 132,815 | $$4.0M | BUY |
5 dark pool trades shown · $$4.3M preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for VERA
PREVIEWSEPT Investing provides real-time options flow tracking for VERA, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $55 | Mar 19 | 128 | $$85 | 1 | SWEEP |
| CALL | $50 | Mar 19 | 128 | $$100 | 1 | SWEEP |
2 options trades shown · 100% calls
Unusual activity, GEX levels, max pain, and dealer positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Vera Therapeutics, Inc. (VERA) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (3 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →VERA — frequently asked questions
What is VERA stock price today?
Vera Therapeutics, Inc. (VERA) is at $28.91, down 5.13% (-$1.57) at the Nov 12, 2026 close.
Why is VERA stock moving today?
Latest VERA news — Nov 6, 2026: Wedbush trims its valuation estimate for Vera Therapeutics to $29 · Nov 6, 2026: Wedbush keeps Neutral rating on Vera Therapeutics, cuts target to $29
Why did VERA stock move on Nov 6, 2026?
Vera Therapeutics shares fell 2.28% to close at $29.79 after Wedbush lowered its valuation estimate and price target for the stock to $29 while maintaining a Neutral rating. The bearish analyst action weighed on sentiment, with the stock trading in a wide range between $28.04 and $30.84 on volume of about 2.07 million shares.
What is the VERA price target?
The average analyst price target for VERA is $70.50, ranging from $29 to $91, based on 8 analysts. Latest: Wedbush maintains on Nov 6, 2026.
What do analysts rate VERA?
Analyst ratings for VERA: 0 Buy, 9 Hold, 0 Sell — consensus Hold.
Did VERA beat earnings?
VERA last reported on Nov 5, 2026: EPS -$1.30 vs -$1.62 expected — a beat of 19.8%.
Does VERA pay a dividend?
VERA does not currently pay a dividend.
How much debt does VERA have?
Vera Therapeutics, Inc. reported $75M of debt and $49M of cash (Jun 30, 2026).
What are VERA support and resistance levels?
Support: $27.46, $24.84, $23.05. Resistance: $29.56, $32.78, $36.50.
What are insiders doing with VERA?
Insider activity: SELLING, 0 buys and 13 sells in the last 90 days.
What is the latest news on VERA?
Nov 6, 2026: Wedbush trims its valuation estimate for Vera Therapeutics to $29 · Nov 6, 2026: Wedbush keeps Neutral rating on Vera Therapeutics, cuts target to $29